182 related articles for article (PubMed ID: 35981569)
21. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
22. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.
Li X; Pan YF; Chen YB; Wan QQ; Lin YK; Shang TY; Xu MY; Jiang TY; Pei MM; Tan YX; Dong LW; Wan XY
Cell Death Dis; 2024 Apr; 15(4):300. PubMed ID: 38684648
[TBL] [Abstract][Full Text] [Related]
23. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
Shi YH; Ding ZB; Zhou J; Hui B; Shi GM; Ke AW; Wang XY; Dai Z; Peng YF; Gu CY; Qiu SJ; Fan J
Autophagy; 2011 Oct; 7(10):1159-72. PubMed ID: 21691147
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
25. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
[TBL] [Abstract][Full Text] [Related]
26. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
[TBL] [Abstract][Full Text] [Related]
27. Pristimerin synergistically sensitizes conditionally reprogrammed patient derived-primary hepatocellular carcinoma cells to sorafenib through endoplasmic reticulum stress and ROS generation by modulating Akt/FoxO1/p27
Tang Y; Chen J; Li J; Zheng Y; Zhong X; Huang S; Chen B; Peng B; Zou X; Chen X
Phytomedicine; 2021 Jun; 86():153563. PubMed ID: 33951569
[TBL] [Abstract][Full Text] [Related]
28. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma.
Huang CY; Chen LJ; Chen G; Chao TI; Wang CY
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232407
[TBL] [Abstract][Full Text] [Related]
29. Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib.
Yang Y; Sun M; Yao W; Wang F; Li X; Wang W; Li J; Gao Z; Qiu L; You R; Yang C; Ba Q; Wang H
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179631
[TBL] [Abstract][Full Text] [Related]
30. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
Tai WT; Cheng AL; Shiau CW; Huang HP; Huang JW; Chen PJ; Chen KF
J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
[TBL] [Abstract][Full Text] [Related]
31. Synergistic antitumor activity of sorafenib and MG149 in hepatocellular carcinoma cells.
Moon B; Park M; Cho SH; Kim KM; Seo HR; Kim JH; Kim JA
BMB Rep; 2022 Oct; 55(10):506-511. PubMed ID: 35880431
[TBL] [Abstract][Full Text] [Related]
32. Identification of prognostic biomarkers and correlations with immune infiltrates among cGAS-STING in hepatocellular carcinoma.
Qi Z; Yan F; Chen D; Xing W; Li Q; Zeng W; Bi B; Xie J
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33006365
[TBL] [Abstract][Full Text] [Related]
33. Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation.
Ma MKF; Lau EYT; Leung DHW; Lo J; Ho NPY; Cheng LKW; Ma S; Lin CH; Copland JA; Ding J; Lo RCL; Ng IOL; Lee TKW
J Hepatol; 2017 Nov; 67(5):979-990. PubMed ID: 28647567
[TBL] [Abstract][Full Text] [Related]
34. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma.
Liao J; Zeng DN; Li JZ; Hua QM; Xiao Z; He C; Mao K; Zhu LY; Chu Y; Wen WP; Zheng L; Wu Y
Hepatol Int; 2020 Jan; 14(1):80-95. PubMed ID: 31802389
[TBL] [Abstract][Full Text] [Related]
35. LncRNA AC026401.3 interacts with OCT1 to intensify sorafenib and lenvatinib resistance by activating E2F2 signaling in hepatocellular carcinoma.
Wang Y; Tan K; Hu W; Hou Y; Yang G
Exp Cell Res; 2022 Nov; 420(1):113335. PubMed ID: 36084669
[TBL] [Abstract][Full Text] [Related]
36. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
Zhong J; Xiu P; Dong X; Wang F; Wei H; Wang X; Xu Z; Liu F; Li T; Wang Y; Li J
Oncol Rep; 2015 Oct; 34(4):2142-50. PubMed ID: 26252057
[TBL] [Abstract][Full Text] [Related]
37. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
38. Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma.
Xu Y; Sun F; Tian Y; Zeng G; Lei G; Bai Z; Wang Y; Ge X; Wang J; Xiao C; Wang Z; Hu M; Song J; Yang P; Liu R
Int Immunopharmacol; 2024 Mar; 129():111628. PubMed ID: 38320351
[TBL] [Abstract][Full Text] [Related]
39. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
Li R; Yanjiao G; Wubin H; Yue W; Jianhua H; Huachuan Z; Rongjian S; Zhidong L
Oncotarget; 2017 Mar; 8(12):19354-19364. PubMed ID: 28423613
[TBL] [Abstract][Full Text] [Related]
40. Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma.
Yoo JJ; Yu SJ; Na J; Kim K; Cho YY; Lee YB; Cho EJ; Lee JH; Kim YJ; Youn H; Yoon JH
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]